{"protocolSection": {"identificationModule": {"nctId": "NCT02134028", "orgStudyIdInfo": {"id": "LTS12551"}, "secondaryIdInfos": [{"id": "2013-003856-19", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1117-6745", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)", "officialTitle": "Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-08-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-04-30", "studyFirstSubmitQcDate": "2014-05-06", "studyFirstPostDateStruct": {"date": "2014-05-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-10-05", "resultsFirstSubmitQcDate": "2020-10-28", "resultsFirstPostDateStruct": {"date": "2020-11-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-21", "lastUpdatePostDateStruct": {"date": "2022-03-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}, "collaborators": [{"name": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Primary Objective:\n\nTo evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).\n\nSecondary Objectives:\n\nTo evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study.\n\nTo evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to:\n\n* Systemic exposure\n* Anti-drug antibodies\n* Biomarkers", "detailedDescription": "A screening period, up to 3 weeks, applied only for participants who came from DRI12544 study. The total study duration, per participant, was a maximum of 108 weeks (or 111 weeks considering a maximum screening period of 3 weeks for study DRI12544) for the participants enrolled prior to Amendment 04 approval and a maximum of 60 weeks for the participants enrolled after Amendment 04 approval.\n\nFollowing amendment 04 (dated 31 Oct 2016) the open-label treatment duration was amended to 48 weeks (1 year); and the 16-week post-treatment period was shortened to 12 weeks."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 2282, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "dupilumab treatment", "type": "EXPERIMENTAL", "description": "For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1\\* Dose every 2 weeks added to current controller medications.\n\nFor participants coming from other studies: dupilumab 1 \\* Dose SC every 2 weeks added to current controller medications.", "interventionNames": ["Drug: Dupilumab"]}], "interventions": [{"type": "DRUG", "name": "Dupilumab", "description": "Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous", "armGroupLabels": ["dupilumab treatment"], "otherNames": ["SAR231893", "REGN668"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs)", "description": "An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \\[IMP\\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)"}], "secondaryOutcomes": [{"measure": "Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period", "description": "Criteria for potentially clinically significant vital sign abnormalities:\n\n* Systolic blood pressure (SBP): Less than or equal to (\u2264) 95 Adults (\u226490 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (\u2265) 20 mmHg; \u2265 160 Adults (\u2265 119 Adolescents) mmHg and increase from baseline (IFB) \u2265 20 mmHg.\n* Diastolic blood pressure (DBP): \u2264 45 Adults (\u226454 Adolescents) mmHg and DFB \u2265 10 mmHg; \u2265 110 Adults (\u226578 Adolescents) mmHg and IFB \u2265 10 mmHg.\n* Heart rate (HR): \u2264 50 beats per minute (bpm) and DFB \u2265 20 bpm; \u2265 120 bpm and IFB \u2265 20 bpm.\n* Respiratory rate: less than (\\<) 12 breaths/min(b/m); greater than (\\>) 20 b/m.\n* Weight (kg): \u2265 5 percent (%) DFB; \u2265 5% IFB.\n* Temperature: \u2265 38.0 degree Celsius (\u00b0C) rectal/ear/temporal; \u2265 37.5\u00b0C oral; \u2265 37.2\u00b0C axillary.\n\nTEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)"}, {"measure": "Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period", "description": "Criteria for potentially clinically significant abnormalities:\n\n* Hemoglobin (Hb): \u2264 115 grams per liter (g/L)(Male \\[M\\]), \u2264 95 g/L (Female\\[ F\\]) (\\< 100 g/L Adolescents); \u2265 185 g/L (M), \u2265 165 g/L (F) (\u2265 200 g/L Adolescents); DFB \u2265 20 g/L.\n* Hematocrit: \u2264 0.37 volume/volume (v/v) (M); \u2264 0.32 v/v (F) (\\<0.32 v/v Adolescents); \u2265 0.55 v/v (M); 0.5 v/v (F) (\\>0.47 v/v Adolescents).\n* RBCs: \u2265 6 Tera/L.\n* Platelets: \\< 100 Giga(G)/L; \u2265 700 G/L.\n\nTEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)"}, {"measure": "Number of Severe Exacerbation Events", "description": "Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for \u2265 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for \u22653 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)"}, {"measure": "Annualized Event Rate Per Participant-Years for Severe Exacerbation", "description": "The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96", "description": "FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96", "description": "FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96", "description": "FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study"}, {"measure": "Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96", "description": "FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48", "description": "The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Weeks 24, and 48 of this extension study"}, {"measure": "Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48", "description": "ACQ-5 response was defined as change from baseline in ACQ-5 scores \u2265 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "timeFrame": "At Weeks 24, and 48 of this extension study"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48", "description": "The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Weeks 24, and 48 of this extension study"}, {"measure": "Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48", "description": "AQLQ global response was defined as participants with change from baseline in AQLQ global score \u2265 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.", "timeFrame": "At Weeks 24, and 48 of this extension study"}, {"measure": "Serum Concentrations of Dupilumab Over Time Till Week 96", "description": "For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.", "timeFrame": "Baseline of parent study, Weeks 0, 4, 12, 24, 48, 72, and 96 of this extension study"}, {"measure": "Percentage of Participants With Antidrug Antibodies (ADA) Response", "description": "ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as \"30 to \\> 10,000\", where low titer (\\< 1,000); moderate (1,000 \u2264 titer \u2264 10,000) and high titer (\\> 10,000).", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)"}, {"measure": "Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96", "description": "For this analysis, baseline was defined as respective parent study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544", "description": "The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544", "description": "The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study"}, {"measure": "Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544", "description": "The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study"}, {"measure": "Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544", "description": "The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.", "timeFrame": "Baseline of parent study, Weeks 48 and 96 of this extension study"}, {"measure": "Percentage of Participants Achieving a Reduction of 50% or Greater (\u2265 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of \u2265 50% in OCS dose were reported.", "timeFrame": "Weeks 48 and 96 of this extension study"}, {"measure": "Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.", "timeFrame": "Weeks 48, and 96 of this extension study"}, {"measure": "Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}, {"measure": "Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n- Participants with asthma who completed the treatment period in a previous dupilumab asthma clinical study (i.e., PDY14192, EFC13579 or EFC13691) or participants with asthma who completed the treatment and follow-up periods in previous dupilumab asthma Study DRI12544.\n\nExclusion criteria:\n\n- Participants who experienced any hypersensitivity reactions to Investigational Medicinal Product (IMP) in the previous dupilumab asthma study, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab, may present an unreasonable risk for the participant.\n\nThe above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number 840047", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Investigational Site Number 840099", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Investigational Site Number 840087", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Investigational Site Number 840402", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Investigational Site Number 840132", "city": "Little Rock", "state": "Arkansas", "zip": "72209", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Investigational Site Number 840109", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Investigational Site Number 840045", "city": "Long Beach", "state": "California", "zip": "90720", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Investigational Site Number 840019", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840029", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840022", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840044", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Investigational Site Number 840041", "city": "North Hollywood", "state": "California", "zip": "91606", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Investigational Site Number 840014", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Investigational Site Number 840121", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Investigational Site Number 840040", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Investigational Site Number 840403", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840006", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840024", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840130", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840902", "city": "New Haven", "state": "Connecticut", "zip": "06510", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Investigational Site Number 840137", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Investigational Site Number 840071", "city": "Gainesville", "state": "Florida", "zip": "32607", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Investigational Site Number 840115", "city": "Ocoee", "state": "Florida", "zip": "34761", "country": "United States", "geoPoint": {"lat": 28.56917, "lon": -81.54396}}, {"facility": "Investigational Site Number 840055", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Investigational Site Number 840079", "city": "Twin Falls", "state": "Idaho", "zip": "83301", "country": "United States", "geoPoint": {"lat": 42.56297, "lon": -114.46087}}, {"facility": "Investigational Site Number 840101", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site Number 840032", "city": "Fort Mitchell", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Investigational Site Number 840017", "city": "Louisville", "state": "Kentucky", "zip": "40223-5440", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Investigational Site Number 840030", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Investigational Site Number 840064", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Investigational Site Number 840052", "city": "Chevy Chase", "state": "Maryland", "zip": "20815", "country": "United States", "geoPoint": {"lat": 39.00287, "lon": -77.07115}}, {"facility": "Investigational Site Number 840073", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Investigational Site Number 840080", "city": "Owings Mills", "state": "Maryland", "zip": "21117", "country": "United States", "geoPoint": {"lat": 39.41955, "lon": -76.78025}}, {"facility": "Investigational Site Number 840401", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Investigational Site Number 840018", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Investigational Site Number 840002", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840102", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840093", "city": "Saint Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840037", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Investigational Site Number 840078", "city": "Omaha", "state": "Nebraska", "zip": "68124", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Investigational Site Number 840004", "city": "Papillion", "state": "Nebraska", "zip": "27103", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Investigational Site Number 840111", "city": "Brick", "state": "New Jersey", "zip": "08723", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Investigational Site Number 840068", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Investigational Site Number 840011", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}, {"facility": "Investigational Site Number 840065", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Investigational Site Number 840126", "city": "Charlotte", "state": "North Carolina", "zip": "28226", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site Number 840083", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site Number 840108", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Investigational Site Number 840107", "city": "Greensboro", "state": "North Carolina", "zip": "27401", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Investigational Site Number 840907", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Investigational Site Number 840404", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157-1071", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Investigational Site Number 840015", "city": "Cincinnati", "state": "Ohio", "zip": "45236", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Investigational Site Number 840146", "city": "Cincinnati", "state": "Ohio", "zip": "45241", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Investigational Site Number 840049", "city": "Middleburg Heights", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Investigational Site Number 840942", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Investigational Site Number 840112", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Investigational Site Number 840104", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Investigational Site Number 840034", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Investigational Site Number 840031", "city": "Portland", "state": "Oregon", "zip": "97223", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Investigational Site Number 840046", "city": "Bethlehem", "state": "Pennsylvania", "zip": "18020", "country": "United States", "geoPoint": {"lat": 40.62593, "lon": -75.37046}}, {"facility": "Investigational Site Number 840085", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "Investigational Site Number 840067", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Investigational Site Number 840928", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840091", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840082", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Investigational Site Number 840117", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Investigational Site Number 840021", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Investigational Site Number 840062", "city": "Amarillo", "state": "Texas", "zip": "79106", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Investigational Site Number 840038", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Investigational Site Number 840124", "city": "Cypress", "state": "Texas", "zip": "77429", "country": "United States", "geoPoint": {"lat": 29.96911, "lon": -95.69717}}, {"facility": "Investigational Site Number 840023", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840923", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Investigational Site Number 840922", "city": "Fort Worth", "state": "Texas", "zip": "76109", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number 840027", "city": "Fort Worth", "state": "Texas", "zip": "76244", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number 840070", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Investigational Site Number 840118", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Investigational Site Number 840008", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Investigational Site Number 840035", "city": "Draper", "state": "Utah", "zip": "84020", "country": "United States", "geoPoint": {"lat": 40.52467, "lon": -111.86382}}, {"facility": "Investigational Site Number 840077", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Investigational Site Number 840057", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Investigational Site Number 840059", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Investigational Site Number 840951", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "Investigational Site Number 032096", "city": "Bahia Blanca", "zip": "B8000JRB", "country": "Argentina", "geoPoint": {"lat": -38.71959, "lon": -62.27243}}, {"facility": "Investigational Site Number 032004", "city": "Buenos Aires", "zip": "B6500BWQ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032003", "city": "Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032011", "city": "Caba", "zip": "1120", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032097", "city": "Caba", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032001", "city": "Caba", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032010", "city": "Caba", "zip": "C1425FVH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032091", "city": "Caba", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032095", "city": "Capital Federal", "zip": "C1425DUC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032002", "city": "La Plata", "zip": "B1900BNN", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Investigational Site Number 032006", "city": "Rosario", "zip": "S2000BRH", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number 032007", "city": "Rosario", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number 032005", "city": "Rosario", "zip": "S2000JKR", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number 032012", "city": "San Miguel De Tucuman", "zip": "T4000CHE", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Investigational Site Number 032009", "city": "San Miguel De Tucum\u00e1n", "zip": "T4000IAR", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Investigational Site Number 036004", "city": "Adelaide", "zip": "5000", "country": "Australia", "geoPoint": {"lat": -34.92866, "lon": 138.59863}}, {"facility": "Investigational Site Number 036005", "city": "Campbelltown", "zip": "2560", "country": "Australia", "geoPoint": {"lat": -34.06667, "lon": 150.81667}}, {"facility": "Investigational Site Number 036001", "city": "Clayton", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "Investigational Site Number 036008", "city": "Frankston", "zip": "3199", "country": "Australia", "geoPoint": {"lat": -38.14458, "lon": 145.12291}}, {"facility": "Investigational Site Number 036093", "city": "Murdoch", "zip": "6150", "country": "Australia", "geoPoint": {"lat": -32.06987, "lon": 115.83757}}, {"facility": "Investigational Site Number 036003", "city": "Nedlands", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Investigational Site Number 036094", "city": "Parkville", "zip": "3050", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "Investigational Site Number 036009", "city": "Prahran", "zip": "3004", "country": "Australia", "geoPoint": {"lat": -37.85114, "lon": 144.99318}}, {"facility": "Investigational Site Number 036006", "city": "Woolloongabba", "zip": "4102", "country": "Australia", "geoPoint": {"lat": -27.48855, "lon": 153.03655}}, {"facility": "Investigational Site Number 056002", "city": "Brussels", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Investigational Site Number 056003", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Investigational Site Number 056001", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Investigational Site Number 076009", "city": "Florian\u00f3polis", "zip": "88040-970", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Investigational Site Number 076007", "city": "Porto Alegre", "zip": "90020-090", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Investigational Site Number 076001", "city": "Porto Alegre", "zip": "90610-000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Investigational Site Number 076003", "city": "Salvador", "zip": "41940-455", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "Investigational Site Number 076012", "city": "Sao Paulo", "zip": "04266-010", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 076002", "city": "Sorocaba", "zip": "18040-425", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Investigational Site Number 076013", "city": "S\u00e3o Bernardo Do Campo", "zip": "09715-090", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "Investigational Site Number 076006", "city": "S\u00e3o Paulo", "zip": "05437-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 124019", "city": "Burlington", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Investigational Site Number 124009", "city": "Calgary", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Investigational Site Number 124016", "city": "Hamilton", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Investigational Site Number 124003", "city": "Mississauga", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Investigational Site Number 124001", "city": "Montreal", "zip": "H2X 3E4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124012", "city": "Montreal", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124010", "city": "Montreal", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124013", "city": "Ottawa", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Investigational Site Number 124018", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number 124014", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number 124008", "city": "Sherbrooke", "zip": "J1H 5N4", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Investigational Site Number 124015", "city": "Toronto", "zip": "M5G 1E2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124002", "city": "Toronto", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124007", "city": "Trois-Rivieres", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Investigational Site Number 124006", "city": "Vancouver", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number 124017", "city": "Vancouver", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number 152007", "city": "Quillota", "zip": "2260877", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Investigational Site Number 152024", "city": "Santiago", "zip": "7500588", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152005", "city": "Santiago", "zip": "7500692", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152014", "city": "Santiago", "zip": "7500698", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152011", "city": "Santiago", "zip": "7500710", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152018", "city": "Santiago", "zip": "8207257", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152002", "city": "Santiago", "zip": "8380456", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152013", "city": "Santiago", "zip": "8910131", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152023", "city": "Talcahuano", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Investigational Site Number 152008", "city": "Talca", "zip": "3460001", "country": "Chile", "geoPoint": {"lat": -35.4264, "lon": -71.65542}}, {"facility": "Investigational Site Number 152004", "city": "Talca", "country": "Chile", "geoPoint": {"lat": -35.4264, "lon": -71.65542}}, {"facility": "Investigational Site Number 152010", "city": "Valdivia", "zip": "5090145", "country": "Chile", "geoPoint": {"lat": -39.81422, "lon": -73.24589}}, {"facility": "Investigational Site Number 152003", "city": "Vi\u00f1a Del Mar", "zip": "2520024", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Investigational Site Number 152021", "city": "Vi\u00f1a Del Mar", "zip": "2520594", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Investigational Site Number 170001", "city": "Bogota", "zip": "110121", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 170002", "city": "Bogot\u00e1", "zip": "110231", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 208002", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Investigational Site Number 208001", "city": "K\u00f8benhavn Nv", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Investigational Site Number 250009", "city": "Brest", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Investigational Site Number 250004", "city": "La Tronche", "zip": "38700", "country": "France", "geoPoint": {"lat": 45.20429, "lon": 5.73645}}, {"facility": "Investigational Site Number 250010", "city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Investigational Site Number 250013", "city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Investigational Site Number 250006", "city": "Lyon", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Investigational Site Number 250001", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Investigational Site Number 250002", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Investigational Site Number 250005", "city": "Nantes", "zip": "44033", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Investigational Site Number 250007", "city": "Nimes Cedex 9", "zip": "30029", "country": "France", "geoPoint": {"lat": 43.83333, "lon": 4.35}}, {"facility": "Investigational Site Number 250008", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Investigational Site Number 250014", "city": "Vandoeuvre-Les-Nancy Cedex", "zip": "54511", "country": "France", "geoPoint": {"lat": 48.65, "lon": 6.18333}}, {"facility": "Investigational Site Number 276006", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigational Site Number 276003", "city": "Bochum", "zip": "44789", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Investigational Site Number 276010", "city": "Frankfurt Am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Investigational Site Number 276011", "city": "Gro\u00dfhansdorf", "zip": "22927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Investigational Site Number 276009", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Investigational Site Number 276005", "city": "R\u00fcdersdorf Bei Berlin", "zip": "15562", "country": "Germany"}, {"facility": "Investigational Site Number 348301", "city": "Balassagyarmat", "zip": "2660", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Investigational Site Number 348303", "city": "Edel\u00e9ny", "zip": "3780", "country": "Hungary", "geoPoint": {"lat": 48.3, "lon": 20.73333}}, {"facility": "Investigational Site Number 348003", "city": "G\u00f6d\u00f6ll\u00f6", "zip": "2100", "country": "Hungary", "geoPoint": {"lat": 47.59657, "lon": 19.35515}}, {"facility": "Investigational Site Number 376003", "city": "Haifa", "zip": "34362", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Investigational Site Number 376001", "city": "Kfar Saba", "zip": "44281", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Investigational Site Number 376005", "city": "Petah-Tikva", "zip": "49100", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Investigational Site Number 376002", "city": "Rehovot", "zip": "76100", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Investigational Site Number 380010", "city": "Ancona", "zip": "60126", "country": "Italy", "geoPoint": {"lat": 43.5942, "lon": 13.50337}}, {"facility": "Investigational Site Number 380009", "city": "Catania", "zip": "95123", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Investigational Site Number 380004", "city": "Ferrara", "zip": "44124", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "Investigational Site Number 380008", "city": "Foggia", "zip": "71100", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "Investigational Site Number 380002", "city": "Genova", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Investigational Site Number 380003", "city": "Modena", "zip": "41124", "country": "Italy", "geoPoint": {"lat": 44.64783, "lon": 10.92539}}, {"facility": "Investigational Site Number 380007", "city": "Padova", "zip": "35128", "country": "Italy", "geoPoint": {"lat": 45.40797, "lon": 11.88586}}, {"facility": "Investigational Site Number 380099", "city": "Palermo", "zip": "90146", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Investigational Site Number 380001", "city": "Pisa", "zip": "56100", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Investigational Site Number 392185", "city": "Akashi-Shi", "country": "Japan", "geoPoint": {"lat": 34.65522, "lon": 135.00687}}, {"facility": "Investigational Site Number 392009", "city": "Asahi-Shi", "country": "Japan", "geoPoint": {"lat": 35.71667, "lon": 140.65}}, {"facility": "Investigational Site Number 392037", "city": "Chiyoda-Ku", "country": "Japan"}, {"facility": "Investigational Site Number 392002", "city": "Chuo-Ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number 392007", "city": "Chuo-Ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number 392112", "city": "Chuo-Ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number 392012", "city": "Edogawa-Ku", "country": "Japan"}, {"facility": "Investigational Site Number 392137", "city": "Fukuoka-Shi", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Investigational Site Number 392021", "city": "Fukuyama-Shi", "country": "Japan", "geoPoint": {"lat": 34.48333, "lon": 133.36667}}, {"facility": "Investigational Site Number 392030", "city": "Habikino-Shi", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Investigational Site Number 392004", "city": "Himeji-Shi", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Investigational Site Number 392032", "city": "Hirakata-Shi", "country": "Japan", "geoPoint": {"lat": 34.81352, "lon": 135.64914}}, {"facility": "Investigational Site Number 392108", "city": "Hiroshima-Shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number 392158", "city": "Hiroshima-Shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number 392013", "city": "Iizuka-Shi", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"facility": "Investigational Site Number 392042", "city": "Isesaki-Shi", "country": "Japan", "geoPoint": {"lat": 36.31667, "lon": 139.2}}, {"facility": "Investigational Site Number 392023", "city": "Kanazawa-Shi", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Investigational Site Number 392142", "city": "Kasuga-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392119", "city": "Kishiwada-Shi", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Investigational Site Number 392025", "city": "Kobe-Shi", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Investigational Site Number 392162", "city": "Kobe-Shi", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Investigational Site Number 392040", "city": "Kodaira-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392044", "city": "Kokubunji-Shi", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Investigational Site Number 392131", "city": "Koushi-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392010", "city": "Kurashiki-Shi", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Investigational Site Number 392036", "city": "Kyoto-Shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number 392153", "city": "Kyoto-Shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number 392133", "city": "Machida-Shi", "country": "Japan", "geoPoint": {"lat": 35.54028, "lon": 139.45083}}, {"facility": "Investigational Site Number 392135", "city": "Matsuyama-Shi", "country": "Japan", "geoPoint": {"lat": 33.83916, "lon": 132.76574}}, {"facility": "Investigational Site Number 392122", "city": "Minato-Ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number 392144", "city": "Minato-Ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number 392106", "city": "Mizunami-Shi", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 137.25}}, {"facility": "Investigational Site Number 392164", "city": "Muroran-Shi", "country": "Japan", "geoPoint": {"lat": 42.31722, "lon": 140.98806}}, {"facility": "Investigational Site Number 392163", "city": "Nagoya-Shi", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Investigational Site Number 392020", "city": "Naka-Gun", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Investigational Site Number 392005", "city": "Naruto-Shi", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.41667}}, {"facility": "Investigational Site Number 392187", "city": "Obihiro-Shi", "country": "Japan", "geoPoint": {"lat": 42.91722, "lon": 143.20444}}, {"facility": "Investigational Site Number 392177", "city": "Ome-Shi", "country": "Japan", "geoPoint": {"lat": 35.78389, "lon": 139.24306}}, {"facility": "Investigational Site Number 392152", "city": "Osaka Sayama-Shi", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number 392155", "city": "Osaka Sayama-Shi", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number 392170", "city": "Osaki-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392127", "city": "Ota-Ku", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number 392043", "city": "Ota-Shi", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number 392169", "city": "Sagamihara-Shi", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Investigational Site Number 392024", "city": "Sakai-Shi", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 135.46667}}, {"facility": "Investigational Site Number 392011", "city": "Sakaide-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392008", "city": "Sapporo-Shi", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Investigational Site Number 392034", "city": "Sapporo-Shi", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Investigational Site Number 392038", "city": "Setagaya-Ku", "country": "Japan", "geoPoint": {"lat": 35.64825, "lon": 139.65376}}, {"facility": "Investigational Site Number 392179", "city": "Seto-Shi", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "Investigational Site Number 392186", "city": "Shibuya-Ku", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Investigational Site Number 392167", "city": "Shinagawa-Ku", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Investigational Site Number 392130", "city": "Shinjuku-Ku", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Investigational Site Number 392165", "city": "Sumida-Ku", "country": "Japan"}, {"facility": "Investigational Site Number 392146", "city": "Tachikawa-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392173", "city": "Tachikawa-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392006", "city": "Tomakomai-Shi", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Investigational Site Number 392029", "city": "Tsu-Shi", "country": "Japan", "geoPoint": {"lat": 34.73333, "lon": 136.51667}}, {"facility": "Investigational Site Number 392168", "city": "Uozu-Shi", "country": "Japan", "geoPoint": {"lat": 36.8, "lon": 137.4}}, {"facility": "Investigational Site Number 392132", "city": "Urasoe-Shi", "country": "Japan", "geoPoint": {"lat": 26.25902, "lon": 127.73012}}, {"facility": "Investigational Site Number 392045", "city": "Uruma-Shi", "country": "Japan", "geoPoint": {"lat": 26.37609, "lon": 127.85908}}, {"facility": "Investigational Site Number 392014", "city": "Yokohama-Shi", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Investigational Site Number 410002", "city": "Bucheon-Si", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Investigational Site Number 410003", "city": "Cheongju-Si", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Investigational Site Number 410013", "city": "Incheon", "zip": "21565", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Investigational Site Number 410006", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410008", "city": "Seoul", "zip": "03312", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410004", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410012", "city": "Seoul", "zip": "04763", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410005", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410007", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410010", "city": "Seoul", "zip": "06973", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410011", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410001", "city": "Suwon", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Investigational Site Number 484013", "city": "Chihuahua", "zip": "31020", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Investigational Site Number 484006", "city": "Chihuahua", "zip": "31200", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Investigational Site Number 484014", "city": "Cuautitlan Izcalli", "zip": "54769", "country": "Mexico", "geoPoint": {"lat": 19.64388, "lon": -99.21598}}, {"facility": "Investigational Site Number 484005", "city": "Distrito Federal", "zip": "07760", "country": "Mexico", "geoPoint": {"lat": 16.59, "lon": -93.02694}}, {"facility": "Investigational Site Number 484008", "city": "Durango", "zip": "34080", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Investigational Site Number 484001", "city": "Guadalajara", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484004", "city": "Mexico City", "zip": "64718", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigational Site Number 484003", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484007", "city": "Monterrey", "zip": "66465", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484010", "city": "M\u00e9xico", "zip": "06700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigational Site Number 484012", "city": "San Juan Del Rio", "zip": "76800", "country": "Mexico", "geoPoint": {"lat": 20.38886, "lon": -99.99577}}, {"facility": "Investigational Site Number 484011", "city": "Veracruz", "zip": "91910", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Investigational Site Number 528001", "city": "Arnhem", "zip": "6815 AD", "country": "Netherlands", "geoPoint": {"lat": 51.98, "lon": 5.91111}}, {"facility": "Investigational Site Number 528002", "city": "Dordrecht", "zip": "3318 AT", "country": "Netherlands", "geoPoint": {"lat": 51.81, "lon": 4.67361}}, {"facility": "Investigational Site Number 616006", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Investigational Site Number 616004", "city": "Gdansk", "zip": "80-405", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Investigational Site Number 616003", "city": "Gdansk", "zip": "80-952", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Investigational Site Number 616007", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616097", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616001", "city": "Lodz", "zip": "90-141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616005", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616009", "city": "Lodz", "zip": "90-329", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616096", "city": "Poznan", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Investigational Site Number 616098", "city": "Strzelce Opolskie", "zip": "47-100", "country": "Poland", "geoPoint": {"lat": 50.5107, "lon": 18.30056}}, {"facility": "Investigational Site Number 616008", "city": "Warszawa", "zip": "00-013", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigational Site Number 616010", "city": "Warszawa", "zip": "04-141", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigational Site Number 616011", "city": "Znin", "zip": "88-400", "country": "Poland", "geoPoint": {"lat": 52.84958, "lon": 17.71992}}, {"facility": "Investigational Site Number 642104", "city": "Bucharest", "zip": "011461", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigational Site Number 642103", "city": "Bucharest", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigational Site Number 642102", "city": "Cluj-Napoca", "zip": "400162", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642107", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642105", "city": "Timisoara", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 642106", "city": "Timisoara", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 643013", "city": "Ekaterinburg", "zip": "620028", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Investigational Site Number 643096", "city": "Moscow", "zip": "105077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643002", "city": "Moscow", "zip": "109240", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643005", "city": "Moscow", "zip": "115280", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643007", "city": "Moscow", "zip": "117574", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643012", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643001", "city": "Moscow", "zip": "125315", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643006", "city": "Novosibirsk", "zip": "630091", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Investigational Site Number 643091", "city": "Ryazan", "zip": "390039", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "Investigational Site Number 643011", "city": "Saint-Petersburg", "zip": "194223", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643010", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643099", "city": "St-Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643009", "city": "St-Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643008", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Investigational Site Number 710009", "city": "Brandfort", "zip": "9400", "country": "South Africa", "geoPoint": {"lat": -28.70008, "lon": 26.45968}}, {"facility": "Investigational Site Number 710011", "city": "Cape Town", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710001", "city": "Cape Town", "zip": "7530", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710091", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710092", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710002", "city": "Cape Town", "zip": "7764", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710003", "city": "Cape Town", "zip": "8000", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710006", "city": "Durban", "zip": "4071", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Investigational Site Number 710007", "city": "Pretoria", "zip": "0087", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Investigational Site Number 724014", "city": "Barcelona", "zip": "08023", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724002", "city": "Barcelona", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724001", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724010", "city": "Palma De Mallorca", "zip": "07120", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "Investigational Site Number 724006", "city": "Pozuelo De Alarc\u00f3n", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Investigational Site Number 724003", "city": "Sabadell", "zip": "08208", "country": "Spain", "geoPoint": {"lat": 41.54329, "lon": 2.10942}}, {"facility": "Investigational Site Number 724007", "city": "Sant Boi De Llobregat", "zip": "08830", "country": "Spain", "geoPoint": {"lat": 41.34357, "lon": 2.03659}}, {"facility": "Investigational Site Number 724096", "city": "Santiago De Compostela", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Investigational Site Number 724008", "city": "Sevilla", "zip": "41071", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Investigational Site Number 724097", "city": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Investigational Site Number 158008", "city": "New Taipei City", "zip": "23561", "country": "Taiwan", "geoPoint": {"lat": 25.01111, "lon": 121.44583}}, {"facility": "Investigational Site Number 158007", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Investigational Site Number 158009", "city": "Taipei", "zip": "11031", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Investigational Site Number 792002", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Investigational Site Number 792098", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Investigational Site Number 792008", "city": "Bursa", "zip": "16059", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Investigational Site Number 792007", "city": "Istanbul", "zip": "34020", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792001", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792004", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792003", "city": "Istanbul", "zip": "34844", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792005", "city": "Izmir", "zip": "35040", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Investigational Site Number 792090", "city": "Izmir", "zip": "35110", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Investigational Site Number 792013", "city": "Kirikkale", "zip": "71450", "country": "Turkey", "geoPoint": {"lat": 39.84528, "lon": 33.50639}}, {"facility": "Investigational Site Number 792006", "city": "Mersin", "zip": "33070", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Investigational Site Number 792096", "city": "Rize", "zip": "53100", "country": "Turkey", "geoPoint": {"lat": 41.02083, "lon": 40.52194}}, {"facility": "Investigational Site Number 804007", "city": "Chernivtsi", "zip": "58001", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Investigational Site Number 804023", "city": "Dnipro", "zip": "49101", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Investigational Site Number 804009", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804094", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804005", "city": "Kharkiv", "zip": "61058", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804021", "city": "Kharkiv", "zip": "61093", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804001", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804004", "city": "Kyiv", "zip": "03049", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804003", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804008", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804017", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804018", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804020", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804016", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804006", "city": "Odesa", "zip": "65025", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Investigational Site Number 804002", "city": "Poltava", "zip": "36038", "country": "Ukraine", "geoPoint": {"lat": 49.59373, "lon": 34.54073}}, {"facility": "Investigational Site Number 804014", "city": "Ternopil", "zip": "46000", "country": "Ukraine", "geoPoint": {"lat": 49.55589, "lon": 25.60556}}, {"facility": "Investigational Site Number 804019", "city": "Vinnytsya", "zip": "21001", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Investigational Site Number 804015", "city": "Yalta", "zip": "298603", "country": "Ukraine", "geoPoint": {"lat": 44.50218, "lon": 34.16624}}, {"facility": "Investigational Site Number 804022", "city": "Zaporizhzhya", "zip": "69076", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Investigational Site Number 804012", "city": "Zaporizhzhya", "zip": "69118", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Investigational Site Number 826001", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Investigational Site Number 826010", "city": "London", "zip": "W2 1NY", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Investigational Site Number 826009", "city": "Oxford", "zip": "OX3 7LE", "country": "United Kingdom", "geoPoint": {"lat": 51.75222, "lon": -1.25596}}, {"facility": "Investigational Site Number 826007", "city": "Portsmouth", "zip": "PO6 3LY", "country": "United Kingdom", "geoPoint": {"lat": 50.79899, "lon": -1.09125}}, {"facility": "Investigational Site Number 826006", "city": "South Shields", "zip": "NE34 0PL", "country": "United Kingdom", "geoPoint": {"lat": 54.99859, "lon": -1.4323}}]}, "referencesModule": {"references": [{"pmid": "36114102", "type": "DERIVED", "citation": "Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, Ortiz B, Jacob-Nara JA, Deniz Y, Rowe PJ, Ishida M, Arima K. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study. Allergol Int. 2023 Jan;72(1):89-99. doi: 10.1016/j.alit.2022.07.008. Epub 2022 Sep 13."}, {"pmid": "35809937", "type": "DERIVED", "citation": "Lugogo N, Mohan A. Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics? Chest. 2022 Jul;162(1):4-5. doi: 10.1016/j.chest.2022.04.004. No abstract available."}, {"pmid": "35636689", "type": "DERIVED", "citation": "Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28."}, {"pmid": "35217003", "type": "DERIVED", "citation": "Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22."}, {"pmid": "34597534", "type": "DERIVED", "citation": "Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The Total study duration was maximum of 108 weeks for participants enrolled prior to amendment 4 approval and a maximum of 60 weeks for participants enrolled after amendment 4. Following amendment 4 (dated 31 Oct 2016) open-label treatment duration was amended to 48 weeks (1 year); and the 16-week post-treatment period was shortened to 12 weeks.", "recruitmentDetails": "Study was initiated at 365 sites in 27 countries. Participants who successfully completed treatment in studies DRI12544 (NCT01854047),EFC13579 (NCT02414854),EFC13691 (NCT02528214) and PDY14192 (NCT02573233) were eligible to continue their treatment in this extension study LTS12551. Total of 2282 participants were enrolled and treated in this study.", "groups": [{"id": "FG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 milligram (mg) on Day 1 followed by a subcutaneous (SC) dose of dupilumab 300 mg every 2 weeks (q2w) for 96 weeks in combination with inhaled corticosteroid (ICS) therapy/long-acting beta-agonist (LABA) therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with oral corticosteroids (OCS) and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "FG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Participants who completed studies DRI12544, PDY14192, EFC13579, and EFC13691.", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "421"}, {"groupId": "FG002", "numSubjects": "517"}, {"groupId": "FG003", "numSubjects": "1013"}, {"groupId": "FG004", "numSubjects": "97"}, {"groupId": "FG005", "numSubjects": "90"}, {"groupId": "FG006", "numSubjects": "19"}, {"groupId": "FG007", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "102"}, {"groupId": "FG001", "numSubjects": "379"}, {"groupId": "FG002", "numSubjects": "465"}, {"groupId": "FG003", "numSubjects": "908"}, {"groupId": "FG004", "numSubjects": "83"}, {"groupId": "FG005", "numSubjects": "76"}, {"groupId": "FG006", "numSubjects": "15"}, {"groupId": "FG007", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "42"}, {"groupId": "FG002", "numSubjects": "52"}, {"groupId": "FG003", "numSubjects": "105"}, {"groupId": "FG004", "numSubjects": "14"}, {"groupId": "FG005", "numSubjects": "14"}, {"groupId": "FG006", "numSubjects": "4"}, {"groupId": "FG007", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Poor compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}, {"type": "Other unspecified", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "33"}, {"groupId": "FG003", "numSubjects": "64"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "6"}, {"groupId": "FG006", "numSubjects": "2"}, {"groupId": "FG007", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "32"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "5"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Analysis was performed on all enrolled participants.", "groups": [{"id": "BG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "BG008", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "421"}, {"groupId": "BG002", "value": "517"}, {"groupId": "BG003", "value": "1013"}, {"groupId": "BG004", "value": "97"}, {"groupId": "BG005", "value": "90"}, {"groupId": "BG006", "value": "19"}, {"groupId": "BG007", "value": "14"}, {"groupId": "BG008", "value": "2282"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "<18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "55"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "89"}]}]}, {"title": "18-64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "101"}, {"groupId": "BG001", "value": "374"}, {"groupId": "BG002", "value": "422"}, {"groupId": "BG003", "value": "826"}, {"groupId": "BG004", "value": "81"}, {"groupId": "BG005", "value": "80"}, {"groupId": "BG006", "value": "19"}, {"groupId": "BG007", "value": "14"}, {"groupId": "BG008", "value": "1917"}]}]}, {"title": "65-74 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "59"}, {"groupId": "BG003", "value": "112"}, {"groupId": "BG004", "value": "14"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "241"}]}]}, {"title": "75-84 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "20"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "35"}]}]}, {"title": "\u226585 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "259"}, {"groupId": "BG002", "value": "335"}, {"groupId": "BG003", "value": "618"}, {"groupId": "BG004", "value": "57"}, {"groupId": "BG005", "value": "53"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "10"}, {"groupId": "BG008", "value": "1408"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "162"}, {"groupId": "BG002", "value": "182"}, {"groupId": "BG003", "value": "395"}, {"groupId": "BG004", "value": "40"}, {"groupId": "BG005", "value": "37"}, {"groupId": "BG006", "value": "12"}, {"groupId": "BG007", "value": "4"}, {"groupId": "BG008", "value": "874"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "2"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "51"}, {"groupId": "BG003", "value": "116"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "1"}, {"groupId": "BG008", "value": "257"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "3"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "2"}, {"groupId": "BG006", "value": "2"}, {"groupId": "BG007", "value": "1"}, {"groupId": "BG008", "value": "75"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "339"}, {"groupId": "BG002", "value": "445"}, {"groupId": "BG003", "value": "844"}, {"groupId": "BG004", "value": "91"}, {"groupId": "BG005", "value": "86"}, {"groupId": "BG006", "value": "17"}, {"groupId": "BG007", "value": "12"}, {"groupId": "BG008", "value": "1922"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "23"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs)", "description": "An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment emergent AE period (time from first dose of investigational medicinal product \\[IMP\\] in LTS12551 up to the last dose of dupilumab plus 14 weeks). A Serious AE (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.", "populationDescription": "Analysis was performed on exposed population which included participants who actually received at least 1 dose or part of a dose of the IMP in LTS12551 study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Any TEAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "369"}, {"groupId": "OG002", "value": "414"}, {"groupId": "OG003", "value": "789"}, {"groupId": "OG004", "value": "74"}, {"groupId": "OG005", "value": "70"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "13"}]}]}, {"title": "Any treatment emergent SAE", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "106"}, {"groupId": "OG004", "value": "12"}, {"groupId": "OG005", "value": "10"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "4"}]}]}, {"title": "Any TEAE leading to death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Any TEAE leading to permanent discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "31"}, {"groupId": "OG004", "value": "4"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period", "description": "Criteria for potentially clinically significant vital sign abnormalities:\n\n* Systolic blood pressure (SBP): Less than or equal to (\u2264) 95 Adults (\u226490 Adolescents) millimeters of mercury (mmHg) and decrease from baseline (DFB) greater than or equal to (\u2265) 20 mmHg; \u2265 160 Adults (\u2265 119 Adolescents) mmHg and increase from baseline (IFB) \u2265 20 mmHg.\n* Diastolic blood pressure (DBP): \u2264 45 Adults (\u226454 Adolescents) mmHg and DFB \u2265 10 mmHg; \u2265 110 Adults (\u226578 Adolescents) mmHg and IFB \u2265 10 mmHg.\n* Heart rate (HR): \u2264 50 beats per minute (bpm) and DFB \u2265 20 bpm; \u2265 120 bpm and IFB \u2265 20 bpm.\n* Respiratory rate: less than (\\<) 12 breaths/min(b/m); greater than (\\>) 20 b/m.\n* Weight (kg): \u2265 5 percent (%) DFB; \u2265 5% IFB.\n* Temperature: \u2265 38.0 degree Celsius (\u00b0C) rectal/ear/temporal; \u2265 37.5\u00b0C oral; \u2265 37.2\u00b0C axillary.\n\nTEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "SBP: \u2264 95 (\u226490) & DFB \u2265 20 mmHg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "19"}, {"groupId": "OG003", "value": "40"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "2"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "SBP: \u2265 160 (\u2265119) & IFB \u2265 20 mmHg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "45"}, {"groupId": "OG004", "value": "6"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "3"}]}]}, {"title": "DBP: \u2264 45 (\u226454) & DFB \u2265 10 mmHg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "DBP: \u2265 110 (\u226578) & IFB \u2265 10 mmHg", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "20"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "HR: \u2264 50 & DFB \u2265 20 bpm", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "12"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "HR: \u2265 120 & IFB \u2265 20 bpm", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "5"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Respiratory rate: < 12 b/m", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "4"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "2"}, {"groupId": "OG007", "value": "3"}]}]}, {"title": "Respiratory rate: > 20 b/m", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "88"}, {"groupId": "OG003", "value": "195"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "12"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Weight: \u2265 5% DFB", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "146"}, {"groupId": "OG003", "value": "261"}, {"groupId": "OG004", "value": "22"}, {"groupId": "OG005", "value": "29"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "3"}]}]}, {"title": "Weight: \u2265 5% IFB", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "485"}, {"groupId": "OG003", "value": "958"}, {"groupId": "OG004", "value": "96"}, {"groupId": "OG005", "value": "89"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "181"}, {"groupId": "OG002", "value": "189"}, {"groupId": "OG003", "value": "378"}, {"groupId": "OG004", "value": "29"}, {"groupId": "OG005", "value": "37"}, {"groupId": "OG006", "value": "8"}, {"groupId": "OG007", "value": "5"}]}]}, {"title": "Temperature: \u2265 38.0\u00b0C", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Temperature: \u2265 37.5\u00b0C", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Temperature: \u2265 37.2\u00b0C", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "516"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "16"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period", "description": "Criteria for potentially clinically significant abnormalities:\n\n* Hemoglobin (Hb): \u2264 115 grams per liter (g/L)(Male \\[M\\]), \u2264 95 g/L (Female\\[ F\\]) (\\< 100 g/L Adolescents); \u2265 185 g/L (M), \u2265 165 g/L (F) (\u2265 200 g/L Adolescents); DFB \u2265 20 g/L.\n* Hematocrit: \u2264 0.37 volume/volume (v/v) (M); \u2264 0.32 v/v (F) (\\<0.32 v/v Adolescents); \u2265 0.55 v/v (M); 0.5 v/v (F) (\\>0.47 v/v Adolescents).\n* RBCs: \u2265 6 Tera/L.\n* Platelets: \\< 100 Giga(G)/L; \u2265 700 G/L.\n\nTEAE period was defined as the time from first dose of IMP in LTS12551 up to the last dose of dupilumab plus 14 weeks.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Hb: \u2264 115 g/L, \u2264 95 g/L (< 100 g/L)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1009"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "29"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "3"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Hb: \u2265 185 g/L, \u2265 165 g/L(\u2265 200 g/L)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1009"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "4"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Hb: DFB \u2265 20 g/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "513"}, {"groupId": "OG003", "value": "1008"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "118"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "7"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Hematocrit: \u2264 0.37 v/v; \u2264 0.32 v/v(<0.32 v/v)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1007"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "23"}, {"groupId": "OG003", "value": "47"}, {"groupId": "OG004", "value": "3"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Hematocrit: \u2265 0.55 v/v; \u2265 0.5 v/v(>0.47 v/v)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1007"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "36"}, {"groupId": "OG004", "value": "3"}, {"groupId": "OG005", "value": "3"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "RBCs: \u2265 6 Tera/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1009"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Platelets: < 100G/ L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1007"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "Platelets: \u2265 700 G/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "514"}, {"groupId": "OG003", "value": "1007"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Severe Exacerbation Events", "description": "Severe asthma exacerbation events were defined as a deterioration of asthma which required: use of systemic corticosteroids for \u2265 3 days, (participants from study EFC13691 (NCT02528214), and who were taking systemic corticosteroids: the use of systemic corticosteroids at least double the current dose and for \u22653 days.) or, hospitalization or emergency room visit because of asthma, required systemic corticosteroids.", "populationDescription": "Analysis was performed on exposed population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of events", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "242"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "437"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "41"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Event Rate Per Participant-Years for Severe Exacerbation", "description": "The annualized event rate per participant-years was defined as the total number of events that occurred during the treatment period divided by the total number of participant-years during the treatment period.", "populationDescription": "Analysis was performed on exposed population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "exacerbation per participant-years", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.314"}, {"groupId": "OG001", "value": "0.330"}, {"groupId": "OG002", "value": "0.351"}, {"groupId": "OG003", "value": "0.331"}, {"groupId": "OG004", "value": "0.302"}, {"groupId": "OG005", "value": "0.391"}, {"groupId": "OG006", "value": "0.149"}, {"groupId": "OG007", "value": "0.077"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96", "description": "FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "396"}, {"groupId": "OG002", "value": "486"}, {"groupId": "OG003", "value": "951"}, {"groupId": "OG004", "value": "88"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.24", "spread": "0.42"}, {"groupId": "OG001", "value": "0.28", "spread": "0.45"}, {"groupId": "OG002", "value": "0.34", "spread": "0.44"}, {"groupId": "OG003", "value": "0.36", "spread": "0.53"}, {"groupId": "OG004", "value": "0.31", "spread": "0.50"}, {"groupId": "OG005", "value": "0.33", "spread": "0.53"}, {"groupId": "OG006", "value": "0.23", "spread": "0.40"}, {"groupId": "OG007", "value": "0.01", "spread": "0.21"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "380"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "447"}, {"groupId": "OG004", "value": "32"}, {"groupId": "OG005", "value": "28"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "spread": "0.44"}, {"groupId": "OG001", "value": "0.27", "spread": "0.46"}, {"groupId": "OG002", "value": "0.33", "spread": "0.44"}, {"groupId": "OG003", "value": "0.31", "spread": "0.47"}, {"groupId": "OG004", "value": "0.36", "spread": "0.66"}, {"groupId": "OG005", "value": "0.25", "spread": "0.46"}, {"groupId": "OG006", "value": "0.14", "spread": "0.41"}, {"groupId": "OG007", "value": "0.01", "spread": "0.12"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96", "description": "FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent predicted FEV1", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "396"}, {"groupId": "OG002", "value": "486"}, {"groupId": "OG003", "value": "951"}, {"groupId": "OG004", "value": "88"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.21", "spread": "13.61"}, {"groupId": "OG001", "value": "10.42", "spread": "14.61"}, {"groupId": "OG002", "value": "11.74", "spread": "14.27"}, {"groupId": "OG003", "value": "12.16", "spread": "16.58"}, {"groupId": "OG004", "value": "10.45", "spread": "15.03"}, {"groupId": "OG005", "value": "12.41", "spread": "18.27"}, {"groupId": "OG006", "value": "5.88", "spread": "10.06"}, {"groupId": "OG007", "value": "1.36", "spread": "8.35"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "380"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "447"}, {"groupId": "OG004", "value": "32"}, {"groupId": "OG005", "value": "28"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.86", "spread": "14.47"}, {"groupId": "OG001", "value": "10.68", "spread": "15.10"}, {"groupId": "OG002", "value": "12.53", "spread": "14.50"}, {"groupId": "OG003", "value": "11.25", "spread": "14.55"}, {"groupId": "OG004", "value": "13.06", "spread": "19.57"}, {"groupId": "OG005", "value": "10.00", "spread": "15.79"}, {"groupId": "OG006", "value": "4.20", "spread": "9.60"}, {"groupId": "OG007", "value": "2.00", "spread": "2.83"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96", "description": "FVC was a standard pulmonary function test used to quantify respiratory muscle weakness. FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "396"}, {"groupId": "OG002", "value": "486"}, {"groupId": "OG003", "value": "951"}, {"groupId": "OG004", "value": "88"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "spread": "0.45"}, {"groupId": "OG001", "value": "0.25", "spread": "0.50"}, {"groupId": "OG002", "value": "0.30", "spread": "0.48"}, {"groupId": "OG003", "value": "0.35", "spread": "0.60"}, {"groupId": "OG004", "value": "0.29", "spread": "0.56"}, {"groupId": "OG005", "value": "0.38", "spread": "0.56"}, {"groupId": "OG006", "value": "0.21", "spread": "0.42"}, {"groupId": "OG007", "value": "0.05", "spread": "0.30"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "380"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "447"}, {"groupId": "OG004", "value": "32"}, {"groupId": "OG005", "value": "28"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.47"}, {"groupId": "OG001", "value": "0.22", "spread": "0.52"}, {"groupId": "OG002", "value": "0.27", "spread": "0.48"}, {"groupId": "OG003", "value": "0.25", "spread": "0.50"}, {"groupId": "OG004", "value": "0.38", "spread": "0.82"}, {"groupId": "OG005", "value": "0.22", "spread": "0.42"}, {"groupId": "OG006", "value": "0.08", "spread": "0.29"}, {"groupId": "OG007", "value": "0.05", "spread": "0.40"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96", "description": "FEF was the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF 25-75% was defined as the mean FEF between 25% and 75% of the FVC, where FVC was defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/second", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "396"}, {"groupId": "OG002", "value": "486"}, {"groupId": "OG003", "value": "951"}, {"groupId": "OG004", "value": "88"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "spread": "0.55"}, {"groupId": "OG001", "value": "0.31", "spread": "0.55"}, {"groupId": "OG002", "value": "0.39", "spread": "0.57"}, {"groupId": "OG003", "value": "0.39", "spread": "0.66"}, {"groupId": "OG004", "value": "0.34", "spread": "0.56"}, {"groupId": "OG005", "value": "0.29", "spread": "0.66"}, {"groupId": "OG006", "value": "0.23", "spread": "0.44"}, {"groupId": "OG007", "value": "0.04", "spread": "0.26"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "380"}, {"groupId": "OG002", "value": "219"}, {"groupId": "OG003", "value": "447"}, {"groupId": "OG004", "value": "32"}, {"groupId": "OG005", "value": "28"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "spread": "0.57"}, {"groupId": "OG001", "value": "0.32", "spread": "0.55"}, {"groupId": "OG002", "value": "0.38", "spread": "0.53"}, {"groupId": "OG003", "value": "0.36", "spread": "0.61"}, {"groupId": "OG004", "value": "0.42", "spread": "0.64"}, {"groupId": "OG005", "value": "0.27", "spread": "0.53"}, {"groupId": "OG006", "value": "0.19", "spread": "0.41"}, {"groupId": "OG007", "value": "0.04", "spread": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48", "description": "The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total mean score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), higher scores indicated lower asthma control. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Weeks 24, and 48 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "513"}, {"groupId": "OG003", "value": "1005"}, {"groupId": "OG004", "value": "96"}, {"groupId": "OG005", "value": "87"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.37", "spread": "0.91"}, {"groupId": "OG001", "value": "-1.48", "spread": "1.10"}, {"groupId": "OG002", "value": "-1.61", "spread": "1.08"}, {"groupId": "OG003", "value": "-1.68", "spread": "1.05"}, {"groupId": "OG004", "value": "-1.09", "spread": "1.10"}, {"groupId": "OG005", "value": "-1.15", "spread": "1.17"}, {"groupId": "OG006", "value": "-0.96", "spread": "1.03"}, {"groupId": "OG007", "value": "-0.80", "spread": "0.46"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "400"}, {"groupId": "OG002", "value": "488"}, {"groupId": "OG003", "value": "957"}, {"groupId": "OG004", "value": "90"}, {"groupId": "OG005", "value": "78"}, {"groupId": "OG006", "value": "15"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "spread": "1.07"}, {"groupId": "OG001", "value": "-1.57", "spread": "1.11"}, {"groupId": "OG002", "value": "-1.64", "spread": "1.08"}, {"groupId": "OG003", "value": "-1.69", "spread": "1.08"}, {"groupId": "OG004", "value": "-1.21", "spread": "1.00"}, {"groupId": "OG005", "value": "-1.06", "spread": "1.25"}, {"groupId": "OG006", "value": "-0.89", "spread": "1.02"}, {"groupId": "OG007", "value": "-0.87", "spread": "0.58"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48", "description": "ACQ-5 response was defined as change from baseline in ACQ-5 scores \u2265 0.5. The ACQ-5 had 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 mean total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "At Weeks 24, and 48 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "513"}, {"groupId": "OG003", "value": "1005"}, {"groupId": "OG004", "value": "96"}, {"groupId": "OG005", "value": "87"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "82.7"}, {"groupId": "OG001", "value": "80.8"}, {"groupId": "OG002", "value": "84.0"}, {"groupId": "OG003", "value": "86.5"}, {"groupId": "OG004", "value": "67.7"}, {"groupId": "OG005", "value": "70.1"}, {"groupId": "OG006", "value": "57.9"}, {"groupId": "OG007", "value": "69.2"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "400"}, {"groupId": "OG002", "value": "488"}, {"groupId": "OG003", "value": "957"}, {"groupId": "OG004", "value": "90"}, {"groupId": "OG005", "value": "78"}, {"groupId": "OG006", "value": "15"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "79.0"}, {"groupId": "OG001", "value": "82.3"}, {"groupId": "OG002", "value": "85.7"}, {"groupId": "OG003", "value": "86.7"}, {"groupId": "OG004", "value": "75.6"}, {"groupId": "OG005", "value": "70.5"}, {"groupId": "OG006", "value": "60.0"}, {"groupId": "OG007", "value": "72.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48", "description": "The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), and environmental stimuli (4 items). Each item was scored on a 7-point likert scale ranged from 1=severely impaired to 7=not impaired. The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired); higher scores indicated better quality of life. For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed for the participants from Studies DRI12544, EFC13579, and EFC13691 only.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Weeks 24, and 48 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}]}], "classes": [{"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "413"}, {"groupId": "OG002", "value": "495"}, {"groupId": "OG003", "value": "948"}, {"groupId": "OG004", "value": "95"}, {"groupId": "OG005", "value": "88"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "spread": "0.99"}, {"groupId": "OG001", "value": "1.28", "spread": "1.24"}, {"groupId": "OG002", "value": "1.38", "spread": "1.15"}, {"groupId": "OG003", "value": "1.38", "spread": "1.16"}, {"groupId": "OG004", "value": "0.99", "spread": "1.10"}, {"groupId": "OG005", "value": "0.97", "spread": "1.26"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "397"}, {"groupId": "OG002", "value": "473"}, {"groupId": "OG003", "value": "908"}, {"groupId": "OG004", "value": "90"}, {"groupId": "OG005", "value": "79"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "spread": "1.13"}, {"groupId": "OG001", "value": "1.40", "spread": "1.19"}, {"groupId": "OG002", "value": "1.39", "spread": "1.17"}, {"groupId": "OG003", "value": "1.40", "spread": "1.18"}, {"groupId": "OG004", "value": "1.06", "spread": "0.98"}, {"groupId": "OG005", "value": "1.00", "spread": "1.23"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48", "description": "AQLQ global response was defined as participants with change from baseline in AQLQ global score \u2265 0.5. The AQLQ was designed to measure the functional impairments that are most troublesome to adults as a result of their asthma. The AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=severely impaired, 7=not impaired). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired). Higher scores indicated better quality of life.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed for the participants from Studies DRI12544, EFC13579, and EFC13691 only.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "At Weeks 24, and 48 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}]}], "classes": [{"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "413"}, {"groupId": "OG002", "value": "495"}, {"groupId": "OG003", "value": "948"}, {"groupId": "OG004", "value": "95"}, {"groupId": "OG005", "value": "88"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "67.6"}, {"groupId": "OG001", "value": "73.6"}, {"groupId": "OG002", "value": "77.6"}, {"groupId": "OG003", "value": "77.2"}, {"groupId": "OG004", "value": "64.2"}, {"groupId": "OG005", "value": "61.4"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "397"}, {"groupId": "OG002", "value": "473"}, {"groupId": "OG003", "value": "908"}, {"groupId": "OG004", "value": "90"}, {"groupId": "OG005", "value": "79"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "65.0"}, {"groupId": "OG001", "value": "76.3"}, {"groupId": "OG002", "value": "77.4"}, {"groupId": "OG003", "value": "78.4"}, {"groupId": "OG004", "value": "73.3"}, {"groupId": "OG005", "value": "68.4"}]}]}]}, {"type": "SECONDARY", "title": "Serum Concentrations of Dupilumab Over Time Till Week 96", "description": "For this analysis, baseline was defined as respective parent study baseline. Here, 'number analyzed'=number of participants with available data for each specified category.", "populationDescription": "Analysis was performed on Pharmacokinetics (PK) population which consisted of all the participants who had actually received at least one dose or part of a dose of dupilumab in the LTS12551 study, with at least one non-missing and evaluable pre-dose serum concentration value after the first dose of dupilumab in the LTS12551 study.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "nanogram per milliliter (ng/mL)", "timeFrame": "Baseline of parent study, Weeks 0, 4, 12, 24, 48, 72, and 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "515"}, {"groupId": "OG003", "value": "1008"}, {"groupId": "OG004", "value": "96"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "413"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "993"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "88"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.000"}, {"groupId": "OG001", "value": "0.00", "spread": "1990.640"}, {"groupId": "OG003", "value": "0.00", "spread": "2286.888"}, {"groupId": "OG005", "value": "0.00", "spread": "0.000"}, {"groupId": "OG007", "value": "0.00", "spread": "0.000"}]}]}, {"title": "Week 0", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "417"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "968"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "88"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.000"}, {"groupId": "OG001", "value": "0.00", "spread": "0.000"}, {"groupId": "OG003", "value": "37230.97", "spread": "73.261"}, {"groupId": "OG005", "value": "40754.49", "spread": "54.858"}, {"groupId": "OG007", "value": "52545.41", "spread": "44.678"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "414"}, {"groupId": "OG002", "value": "500"}, {"groupId": "OG003", "value": "971"}, {"groupId": "OG004", "value": "93"}, {"groupId": "OG005", "value": "88"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "13"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46848.70", "spread": "43.149"}, {"groupId": "OG001", "value": "40704.77", "spread": "47.293"}, {"groupId": "OG002", "value": "25847.86", "spread": "49.371"}, {"groupId": "OG003", "value": "50566.66", "spread": "55.104"}, {"groupId": "OG004", "value": "25868.25", "spread": "53.450"}, {"groupId": "OG005", "value": "48295.93", "spread": "52.655"}, {"groupId": "OG006", "value": "23336.89", "spread": "50.542"}, {"groupId": "OG007", "value": "56486.58", "spread": "45.755"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "417"}, {"groupId": "OG002", "value": "501"}, {"groupId": "OG003", "value": "973"}, {"groupId": "OG004", "value": "94"}, {"groupId": "OG005", "value": "87"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "54467.13", "spread": "50.267"}, {"groupId": "OG001", "value": "48155.26", "spread": "52.353"}, {"groupId": "OG002", "value": "45406.55", "spread": "51.399"}, {"groupId": "OG003", "value": "55140.49", "spread": "53.114"}, {"groupId": "OG004", "value": "44064.95", "spread": "57.100"}, {"groupId": "OG005", "value": "50904.34", "spread": "51.233"}, {"groupId": "OG006", "value": "49026.51", "spread": "41.619"}, {"groupId": "OG007", "value": "55365.35", "spread": "53.317"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "405"}, {"groupId": "OG002", "value": "500"}, {"groupId": "OG003", "value": "973"}, {"groupId": "OG004", "value": "90"}, {"groupId": "OG005", "value": "83"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "47023.84", "spread": "51.645"}, {"groupId": "OG001", "value": "49730.56", "spread": "53.625"}, {"groupId": "OG002", "value": "50984.57", "spread": "53.744"}, {"groupId": "OG003", "value": "54897.58", "spread": "54.044"}, {"groupId": "OG004", "value": "57363.72", "spread": "57.889"}, {"groupId": "OG005", "value": "44219.42", "spread": "55.383"}, {"groupId": "OG006", "value": "63080.82", "spread": "51.224"}, {"groupId": "OG007", "value": "60643.16", "spread": "41.617"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "397"}, {"groupId": "OG002", "value": "484"}, {"groupId": "OG003", "value": "951"}, {"groupId": "OG004", "value": "89"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "16"}, {"groupId": "OG007", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46355.26", "spread": "52.612"}, {"groupId": "OG001", "value": "45919.75", "spread": "55.932"}, {"groupId": "OG002", "value": "41867.50", "spread": "60.345"}, {"groupId": "OG003", "value": "41849.96", "spread": "62.049"}, {"groupId": "OG004", "value": "36219.47", "spread": "67.530"}, {"groupId": "OG005", "value": "36564.41", "spread": "60.959"}, {"groupId": "OG006", "value": "24864.79", "spread": "58.016"}, {"groupId": "OG007", "value": "53320.11", "spread": "46.714"}]}]}, {"title": "Week 72", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "385"}, {"groupId": "OG002", "value": "227"}, {"groupId": "OG003", "value": "453"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "29"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "44771.52", "spread": "56.256"}, {"groupId": "OG001", "value": "46842.64", "spread": "53.335"}, {"groupId": "OG002", "value": "45628.10", "spread": "56.232"}, {"groupId": "OG003", "value": "46372.55", "spread": "57.719"}, {"groupId": "OG004", "value": "60117.76", "spread": "62.390"}, {"groupId": "OG005", "value": "32029.19", "spread": "66.785"}, {"groupId": "OG006", "value": "40362.88", "spread": "55.567"}, {"groupId": "OG007", "value": "26383.90", "spread": "120.013"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "381"}, {"groupId": "OG002", "value": "222"}, {"groupId": "OG003", "value": "446"}, {"groupId": "OG004", "value": "33"}, {"groupId": "OG005", "value": "29"}, {"groupId": "OG006", "value": "5"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "42431.08", "spread": "59.222"}, {"groupId": "OG001", "value": "42661.18", "spread": "59.658"}, {"groupId": "OG002", "value": "38908.58", "spread": "64.633"}, {"groupId": "OG003", "value": "39088.60", "spread": "62.897"}, {"groupId": "OG004", "value": "49810.65", "spread": "65.546"}, {"groupId": "OG005", "value": "19030.70", "spread": "67.237"}, {"groupId": "OG006", "value": "42360.37", "spread": "49.409"}, {"groupId": "OG007", "value": "56378.01", "spread": "7.140"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Antidrug Antibodies (ADA) Response", "description": "ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as an ADA positive response in the assay post first dose in LTS12551, when baseline results were negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive. The criteria for positive was defined as \"30 to \\> 10,000\", where low titer (\\< 1,000); moderate (1,000 \u2264 titer \u2264 10,000) and high titer (\\> 10,000).", "populationDescription": "Analysis was performed on ADA population which consisted of all participants who had actually received at least one dose or part of a dose of dupilumab in the LTS12551 study, with at least one pre-dose sample that was assayed successfully using the ADA assay after the first dose of dupilumab in the LTS12551 study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From the first IMP injection in LTS12551 to the last IMP injection plus 2 weeks (up to 96 weeks)", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "515"}, {"groupId": "OG003", "value": "1008"}, {"groupId": "OG004", "value": "95"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Treatment-emergent ADA", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.8"}, {"groupId": "OG001", "value": "12.1"}, {"groupId": "OG002", "value": "9.5"}, {"groupId": "OG003", "value": "4.5"}, {"groupId": "OG004", "value": "7.4"}, {"groupId": "OG005", "value": "8.9"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "7.1"}]}]}, {"title": "Treatment-boosted ADA", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "1.1"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96", "description": "For this analysis, baseline was defined as respective parent study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG002", "title": "Participants From EFC13579: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG003", "title": "Participants From EFC13579: Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG004", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG005", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG006", "title": "Participants From PDY14192: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG007", "title": "Participants From PDY14192: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}, {"groupId": "OG002", "value": "517"}, {"groupId": "OG003", "value": "1013"}, {"groupId": "OG004", "value": "97"}, {"groupId": "OG005", "value": "90"}, {"groupId": "OG006", "value": "19"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "386"}, {"groupId": "OG002", "value": "474"}, {"groupId": "OG003", "value": "935"}, {"groupId": "OG004", "value": "87"}, {"groupId": "OG005", "value": "82"}, {"groupId": "OG006", "value": "14"}, {"groupId": "OG007", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.007", "spread": "0.475"}, {"groupId": "OG001", "value": "-0.041", "spread": "0.588"}, {"groupId": "OG002", "value": "-0.096", "spread": "0.428"}, {"groupId": "OG003", "value": "-0.099", "spread": "0.360"}, {"groupId": "OG004", "value": "0.098", "spread": "0.450"}, {"groupId": "OG005", "value": "0.016", "spread": "0.382"}, {"groupId": "OG006", "value": "-0.066", "spread": "0.181"}, {"groupId": "OG007", "value": "-0.026", "spread": "0.187"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "381"}, {"groupId": "OG002", "value": "218"}, {"groupId": "OG003", "value": "435"}, {"groupId": "OG004", "value": "30"}, {"groupId": "OG005", "value": "29"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.074", "spread": "0.251"}, {"groupId": "OG001", "value": "-0.081", "spread": "0.562"}, {"groupId": "OG002", "value": "-0.161", "spread": "0.391"}, {"groupId": "OG003", "value": "-0.114", "spread": "0.354"}, {"groupId": "OG004", "value": "-0.051", "spread": "0.399"}, {"groupId": "OG005", "value": "0.083", "spread": "0.642"}, {"groupId": "OG006", "value": "-0.103", "spread": "0.039"}, {"groupId": "OG007", "value": "0.025", "spread": "0.134"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544", "description": "The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Morning PEF was performed within 15 minutes after arising (between 5:30 AM and 10 AM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent study DRI12544 baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters per minute (L/min)", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "407"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.26", "spread": "76.71"}, {"groupId": "OG001", "value": "22.95", "spread": "70.06"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "340"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.63", "spread": "83.88"}, {"groupId": "OG001", "value": "21.69", "spread": "77.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544", "description": "The PEF was a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at morning and evening. Evening PEF was performed in the evening (between 5:30 PM and 10 PM) prior to taking any salbutamol/albuterol or levosalbutamol/levalbuterol. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.65", "spread": "75.00"}, {"groupId": "OG001", "value": "11.97", "spread": "72.19"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "327"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.16", "spread": "79.47"}, {"groupId": "OG001", "value": "10.05", "spread": "79.47"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0=no asthma symptoms, slept through the night, 1=slept well, but some complaints in the morning. No nighttime awakenings, 2=woke up once because of asthma (including early awakening), 3=woke up several times because of asthma (including early awakening), 4=bad night, awake most of the night because of asthma; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.49", "spread": "0.78"}, {"groupId": "OG001", "value": "-0.68", "spread": "0.79"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "324"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.52", "spread": "0.90"}, {"groupId": "OG001", "value": "-0.76", "spread": "0.81"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual; higher scores indicated more severe symptoms. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "407"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "spread": "0.81"}, {"groupId": "OG001", "value": "-0.72", "spread": "0.85"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "330"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.49", "spread": "0.94"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.88"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544", "description": "The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations was recorded daily by the participants in an electronic diary/PEF meter. Mean number of inhalations in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "inhalations per day", "timeFrame": "Baseline of parent study, Week 48, and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00", "spread": "3.65"}, {"groupId": "OG001", "value": "0.68", "spread": "4.80"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "325"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "4.17"}, {"groupId": "OG001", "value": "-0.82", "spread": "5.18"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544", "description": "The number of nocturnal awakening because of asthma symptoms were recorded every morning by the participants in an electronic diary. Mean number of awakenings in last 7 days prior to each visit was calculated and was used in computation of data reported. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nocturnal awakenings", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.27", "spread": "0.54"}, {"groupId": "OG001", "value": "-0.43", "spread": "0.89"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "344"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.29", "spread": "0.58"}, {"groupId": "OG001", "value": "-0.49", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. For this analysis, baseline was defined as parent study EFC13691 baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study EFC13691 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline of parent study, Weeks 48 and 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55.32", "spread": "42.98"}, {"groupId": "OG001", "value": "80.23", "spread": "30.44"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.37", "spread": "29.37"}, {"groupId": "OG001", "value": "88.16", "spread": "26.83"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Reduction of 50% or Greater (\u2265 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. Percentage of participants who achieved a reduction of \u2265 50% in OCS dose were reported.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study EFC13691 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 48 and 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "64.9"}, {"groupId": "OG001", "value": "86.0"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "82.1"}, {"groupId": "OG001", "value": "94.7"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691", "description": "OCS was allowed as background controller medication for the participants from study EFC13691 only. Number of participants who gradually discontinued or reduced therapeutic dose were reported in this outcome measure.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study EFC13691 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 48, and 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From EFC13691: Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From EFC13691: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "57"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.2"}, {"groupId": "OG001", "value": "59.6"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "42.9"}, {"groupId": "OG001", "value": "78.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "EQ-5D-3L: validated and reliable self-report health status questionnaire consisted of EQ-5D descriptive system and visual analogue scale (VAS). EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: no problem, some problems, and severe problems. The 5 dimensional 3-level systems was converted into single index utility score, and the score was 0 - 100, where 100=best health state; and 0=worst health state; where higher scores indicated better outcome. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "370"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.20"}, {"groupId": "OG001", "value": "0.14", "spread": "0.21"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.18"}, {"groupId": "OG001", "value": "0.13", "spread": "0.21"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544", "description": "EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. For this analysis, baseline was defined as parent DRI12544 study baseline.", "populationDescription": "Analysis was performed on exposed population. Here, 'number analyzed' = number of participants with available data for each specified category. Data were planned to be collected and analyzed only for the participants from Study DRI12544 and not for the participants from other studies.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline of parent study, Week 48 and Week 96 of this extension study", "groups": [{"id": "OG000", "title": "Participants From DRI12544: Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}, {"id": "OG001", "title": "Participants From DRI12544: Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "421"}]}], "classes": [{"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "370"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.10", "spread": "15.40"}, {"groupId": "OG001", "value": "12.88", "spread": "18.76"}]}]}, {"title": "Week 96", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "294"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.90", "spread": "18.92"}, {"groupId": "OG001", "value": "13.95", "spread": "18.81"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Reported AE and deaths were TEAEs that developed, worsened, or became serious and deaths that occurred during the TEAE period (time from the first dose of dupilumab in LTS12551 up to the last dose of dupilumab plus 14 weeks) (i.e. up to 108 weeks).", "description": "Analysis was performed on safety population.", "eventGroups": [{"id": "EG000", "title": "Participants From DRI12544 Study Placebo/Dupilumab", "description": "Participants who completed treatment of placebo (for dupilumab) and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 111, "seriousNumAffected": 14, "seriousNumAtRisk": 111, "otherNumAffected": 80, "otherNumAtRisk": 111}, {"id": "EG001", "title": "Participants From DRI12544 Study Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab and post-treatment period in study DRI12544, received a loading dose of dupilumab 600 mg on Day 1 followed by a SC dose of dupilumab 300 mg q2w for 96 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 3, "deathsNumAtRisk": 421, "seriousNumAffected": 42, "seriousNumAtRisk": 421, "otherNumAffected": 323, "otherNumAtRisk": 421}, {"id": "EG002", "title": "Participants From EFC13579 Study Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 517, "seriousNumAffected": 48, "seriousNumAtRisk": 517, "otherNumAffected": 357, "otherNumAtRisk": 517}, {"id": "EG003", "title": "Participants From EFC13579 Study Dupilumab/Dupilumab", "description": "Participants who completed the treatment for dupilumab in study EFC13579 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with ICS therapy/LABA therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 1, "deathsNumAtRisk": 1013, "seriousNumAffected": 106, "seriousNumAtRisk": 1013, "otherNumAffected": 666, "otherNumAtRisk": 1013}, {"id": "EG004", "title": "Participants From EFC13691 Study Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 97, "seriousNumAffected": 12, "seriousNumAtRisk": 97, "otherNumAffected": 56, "otherNumAtRisk": 97}, {"id": "EG005", "title": "Participants From EFC13691 Study Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study EFC13691 and, who were enrolled before amendment 4 received a SC dose of dupilumab 300 mg q2w for 96 weeks and those who were enrolled after amendment 4 received a SC dose of dupilumab 300 mg q2w for 48 weeks in combination with OCS and ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 90, "seriousNumAffected": 10, "seriousNumAtRisk": 90, "otherNumAffected": 55, "otherNumAtRisk": 90}, {"id": "EG006", "title": "Participants From PDY14192 Study Placebo/Dupilumab", "description": "Participants who completed the treatment of placebo (for dupilumab) in study PDY14192 received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with CS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 19, "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 18, "otherNumAtRisk": 19}, {"id": "EG007", "title": "Participants From PDY14192 Study Dupilumab/Dupilumab", "description": "Participants who completed the treatment of dupilumab in study PDY14192, received a SC dose of dupilumab 300 mg q2w for up to 96 weeks in combination with ICS therapy in this extension study. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 14, "seriousNumAffected": 4, "seriousNumAtRisk": 14, "otherNumAffected": 13, "otherNumAtRisk": 14}], "seriousEvents": [{"term": "Acute Coronary Syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Acute Left Ventricular Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Aortic Valve Incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 10, "numAffected": 5, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Atrioventricular Block Complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Myocardial Ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Myocarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Odontogenic Cyst", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Angle Closure Glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Serous Retinal Detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Incarcerated Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diaphragmatic Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Diverticulum Intestinal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastritis Erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastroenteritis Eosinophilic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hiatus Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Inguinal Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intestinal Obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intra-Abdominal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Large Intestine Polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Oesophageal Food Impaction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Retroperitoneum Cyst", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tooth Impacted", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Umbilical Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Upper Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Adverse Drug Reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Injection Site Erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cholecystitis Acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hepatomegaly", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Anaphylactic Reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Drug Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Eosinophilic Granulomatosis With Polyangiitis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abscess Limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bronchopulmonary Aspergillosis Allergic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cervicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Chronic Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ear Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Herpes Simplex Encephalitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Large Intestine Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lower Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lower Respiratory Tract Infection Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Mycobacterium Avium Complex Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumonia Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Post Procedural Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyelonephritis Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Salmonellosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sialoadenitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Wound Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Chemical Peritonitis", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Craniocerebral Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Facial Bones Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Forearm Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hand Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Head Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Incision Site Pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Incisional Hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lower Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lumbar Vertebral Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Meniscus Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Post Procedural Complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Post Procedural Constipation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pulmonary Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Radius Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Skin Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Upper Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Alanine Aminotransferase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diabetic Metabolic Decompensation", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pain In Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rotator Cuff Syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Adenocarcinoma Gastric", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Adenocarcinoma Of Colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Basal Cell Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Benign Ovarian Tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bowen's Disease", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Colon Adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Colon Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Endometrial Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fibroadenoma Of Breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Follicular Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastric Adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hodgkin's Disease", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intraductal Proliferative Breast Lesion", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Juvenile Melanoma Benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Large Intestine Benign Neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Lung Cancer Metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Metastases To Central Nervous System", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Non-Small Cell Lung Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Osteochondroma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ovarian Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Papillary Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Prostate Cancer Stage I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rectal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Squamous Cell Carcinoma Of Skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Uterine Leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Carotid Artery Disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cerebral Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dyskinesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypertensive Cerebrovascular Disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Idiopathic Intracranial Hypertension", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Neuritis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Optic Neuritis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Parkinson's Disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Thalamic Infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abortion Spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Depressed Mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Suicide Attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Acute Kidney Injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Iga Nephropathy", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ureterolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Urinary Incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Adenomyosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Benign Prostatic Hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Endometrial Hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Haemorrhagic Ovarian Cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Ovarian Cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vaginal Prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Acute Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 13, "numAffected": 13, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 19, "numAffected": 18, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Atelectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nasal Septum Deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Nasal Septum Perforation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pulmonary Oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sinusitis Noninfective", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Status Asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Vocal Cord Polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Erythema Nodosum", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rash Erythematous", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rash Vesicular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Miscarriage Of Partner", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Aortic Dilatation", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Deep Vein Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Hypertensive Crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}], "otherEvents": [{"term": "Ear Pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 6, "numAffected": 6, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tinnitus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dry Eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 11, "numAffected": 9, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 16, "numAffected": 13, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 11, "numAffected": 10, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dental Caries", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 20, "numAffected": 16, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 9, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 27, "numAffected": 25, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 8, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Gastrointestinal Disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gastrooesophageal Reflux Disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 15, "numAffected": 13, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 23, "numAffected": 21, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Haemorrhoidal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 36, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 52, "numAffected": 14, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 4, "numAffected": 3, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 15, "numAffected": 13, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 5, "numAffected": 4, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 15, "numAffected": 8, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Injection Site Bruising", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Injection Site Erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 102, "numAffected": 26, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 412, "numAffected": 55, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 148, "numAffected": 35, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 295, "numAffected": 50, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 12, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 29, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 21, "numAffected": 8, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 29, "numAffected": 6, "numAtRisk": 14}]}, {"term": "Injection Site Haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 3, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Injection Site Haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Injection Site Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 84, "numAffected": 14, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 32, "numAffected": 14, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 58, "numAffected": 15, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 8, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 6, "numAffected": 3, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 4, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Injection Site Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 28, "numAffected": 18, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 40, "numAffected": 15, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 51, "numAffected": 14, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 9, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 3, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Injection Site Pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 12, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 54, "numAffected": 16, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 36, "numAffected": 15, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 20, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 3, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Injection Site Reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 10, "numAffected": 5, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Injection Site Warmth", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 20, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Peripheral Swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 12, "numAffected": 8, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 20, "numAffected": 16, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 4, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Drug Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Multiple Allergies", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 15, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 135, "numAffected": 80, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 100, "numAffected": 63, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 181, "numAffected": 117, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 10, "numAffected": 9, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 15, "numAffected": 14, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Bronchitis Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 21, "numAffected": 18, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 14, "numAffected": 10, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 31, "numAffected": 26, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Genital Herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Gingivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 52, "numAffected": 44, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 39, "numAffected": 30, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 79, "numAffected": 67, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 11, "numAffected": 9, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 10, "numAffected": 7, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Lower Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 18, "numAffected": 17, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 47, "numAffected": 27, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 208, "numAffected": 109, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 149, "numAffected": 99, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 293, "numAffected": 191, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 30, "numAffected": 17, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 22, "numAffected": 16, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 8, "numAffected": 3, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 8, "numAffected": 6, "numAtRisk": 14}]}, {"term": "Oral Candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 19, "numAffected": 9, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 9, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 19, "numAffected": 14, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 16, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 57, "numAffected": 37, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 30, "numAffected": 26, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 75, "numAffected": 59, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 5, "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pharyngitis Streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Post Procedural Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Postoperative Wound Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Pulpitis Dental", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 6, "numAffected": 5, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 17, "numAffected": 15, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 25, "numAffected": 18, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Respiratory Tract Infection Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 15, "numAffected": 11, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 25, "numAffected": 22, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 56, "numAffected": 33, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 43, "numAffected": 32, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 66, "numAffected": 50, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 4, "numAffected": 4, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 18, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 87, "numAffected": 60, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 96, "numAffected": 65, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 213, "numAffected": 130, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 12, "numAffected": 8, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 15, "numAffected": 6, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 4, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 31, "numAffected": 26, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 20, "numAffected": 17, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 53, "numAffected": 42, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Viral Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 15, "numAffected": 11, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 16, "numAffected": 13, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 48, "numAffected": 30, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Accidental Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 44, "numAffected": 40, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 31, "numAffected": 28, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 48, "numAffected": 45, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 6, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Arthropod Bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 27, "numAffected": 14, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 13, "numAffected": 12, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 18, "numAffected": 14, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 3, "numAffected": 3, "numAtRisk": 14}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 12, "numAffected": 12, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 38, "numAffected": 33, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Intentional Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Limb Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Lip Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Muscle Strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Skin Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Stab Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Tooth Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Wrist Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "C-Reactive Protein Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Epstein-Barr Virus Test Positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "White Blood Cells Urine Positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 29, "numAffected": 23, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 29, "numAffected": 23, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 22, "numAffected": 22, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 7, "numAffected": 7, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 33, "numAffected": 30, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 28, "numAffected": 23, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 67, "numAffected": 52, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 5, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 4, "numAffected": 3, "numAtRisk": 14}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 9, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 10, "numAffected": 9, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 14, "numAffected": 14, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 14, "numAffected": 12, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Myositis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Pain In Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 8, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 16, "numAffected": 16, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rotator Cuff Syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Trismus", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Pituitary Tumour Benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Carpal Tunnel Syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 7, "numAffected": 6, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 3, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dysaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 13, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 141, "numAffected": 47, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 69, "numAffected": 47, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 145, "numAffected": 74, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 9, "numAffected": 4, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 14, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 2, "numAffected": 2, "numAtRisk": 14}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 11, "numAffected": 10, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 8, "numAffected": 8, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sleep Disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Leukocyturia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Urinary Retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 24, "numAffected": 16, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 12, "numAffected": 10, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 29, "numAffected": 22, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 4, "numAffected": 3, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 3, "numAffected": 3, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 23, "numAffected": 12, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 7, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 3, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Nasal Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 11, "numAffected": 11, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 22, "numAffected": 20, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 5, "numAffected": 5, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Paranasal Sinus Discomfort", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Sinus Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Sputum Increased", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Upper Respiratory Tract Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 3, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Dermatitis Atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 2, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 11, "numAffected": 9, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Dyshidrotic Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Papulopustular Rosacea", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Pityriasis Alba", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Rash Generalised", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}, {"term": "Rosacea", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Solar Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 14}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 19, "numAffected": 16, "numAtRisk": 421}, {"groupId": "EG002", "numEvents": 20, "numAffected": 19, "numAtRisk": 517}, {"groupId": "EG003", "numEvents": 37, "numAffected": 29, "numAtRisk": 1013}, {"groupId": "EG004", "numEvents": 7, "numAffected": 5, "numAtRisk": 97}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-US@sanofi.com", "phone": "800-633-1610", "phoneExt": "1#"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-10-31", "uploadDate": "2020-10-04T12:18", "filename": "Prot_000.pdf", "size": 1389180}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-07-20", "uploadDate": "2020-10-04T12:19", "filename": "SAP_001.pdf", "size": 740633}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}